"BCG Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
| Descriptor ID |
D001500
|
| MeSH Number(s) |
D20.215.894.135.825.100
|
| Concept/Terms |
BCG Vaccine- BCG Vaccine
- Vaccine, BCG
- Bacillus Calmette Guerin Vaccine
- Calmette Guerin Bacillus Vaccine
- Calmette's Vaccine
- Calmette Vaccine
- Calmettes Vaccine
- Vaccine, Calmette's
|
Below are MeSH descriptors whose meaning is more general than "BCG Vaccine".
Below are MeSH descriptors whose meaning is more specific than "BCG Vaccine".
This graph shows the total number of publications written about "BCG Vaccine" by people in this website by year, and whether "BCG Vaccine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "BCG Vaccine" by people in Profiles.
-
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
-
Advances in diagnosis and treatment of bladder cancer. BMJ. 2024 02 12; 384:e076743.
-
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022 Oct; 5(5):505-516.
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
-
Human Immunodeficiency Virus Exposure but Not Early Cytomegalovirus Infection Is Associated With Increased Hospitalization and Decreased Memory T-Cell Responses to Tetanus Vaccine. J Infect Dis. 2020 03 16; 221(7):1167-1175.
-
Individual- and community-level determinants of child immunization in the Democratic Republic of Congo: A multilevel analysis. PLoS One. 2018; 13(8):e0202742.
-
Intravesical therapy for bladder cancer. Expert Opin Pharmacother. 2015 Apr; 16(6):889-901.
-
Mycobacterium bovis infection of an axillary-femoral bypass graft after intravesical bacille Calmette-Guérin immunotherapy for bladder cancer. Am J Med Sci. 2009 Jan; 337(1):63-4.
-
Risk-adapted use of intravesical chemotherapy. BJU Int. 2008 Nov; 102(9 Pt B):1247-53.